v3.26.1
Collaborations, contracts and licensing agreements - Revenue from collaborations (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues $ 1,014 $ 10,739 $ 180,140 $ 12,503
Revenue from collaborations and licenses        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues 632 0 179,373 0
Revenue from collaborations and licenses | Acuitas Therapeutics, Inc.        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues 202 591 406 1,095
Revenue from collaborations and licenses | Qilu Pharmaceutical Co, LTD.        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues 0 9,622 0 10,434
Revenue from collaborations and licenses | Genevant        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues 632 0 179,373 0
Non-cash royalty revenue        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues 180 526 361 974
Non-cash royalty revenue | Alnylam Pharmaceuticals, Inc.        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues $ 180 $ 526 $ 361 $ 974